Related Experiment Video

Updated: Jun 3, 2025

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment
11:13

Author Spotlight: Exploring Salidroside's Molecular Mechanisms in Breast Cancer Treatment

Published on: June 9, 2023

1.5K

The Biological Roles and Clinical Applications of the PI3K/AKT Pathway in Targeted Therapy Resistance in

Hanyi Zhong1, Ziling Zhou1, Han Wang1

  • 1Department of General Surgery, Comprehensive Breast Health Center, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai 200025, China.

International Journal of Molecular Sciences
|January 8, 2025
PubMed

Insights

Epidermal growth factor receptor 2-positive breast cancer (HER2+) shows resistance to therapy. Targeting the phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathway offers new hope for treating this aggressive cancer.

Area of Science:

  • Oncology
  • Molecular Biology
  • Pharmacology

Background:

  • HER2-positive breast cancer (HER2+ BC) is aggressive and resistant to HER2-targeted therapy.
  • The phosphatidylinositol-3-kinase/protein kinase B (PI3K/AKT) pathway is crucial in cancer proliferation and drug resistance.
  • Understanding PI3K/AKT pathway alterations is key to overcoming HER2+ BC treatment challenges.

Purpose of the Study:

  • To review the PI3K/AKT pathway's role in HER2+ BC.
  • To explore current and emerging targeted therapies for HER2+ BC.
  • To provide insights into advancing treatment strategies.

Main Methods:

  • Literature review of scientific publications.
  • Analysis of PI3K/AKT pathway alterations in HER2+ BC.
  • Examination of clinical trial data and approved therapies.

Main Results:

  • The PI3K/AKT pathway is frequently altered in HER2+ BC, contributing to drug resistance.
  • Several PI3K/AKT targeted drugs are in development, clinical trials, or approved.
  • Varied patient responses highlight the need for personalized treatment approaches.

Conclusions:

  • Targeting the PI3K/AKT pathway presents a promising strategy for HER2+ BC treatment.
  • Further research is needed to address safety, regulatory, and ethical considerations.
  • Personalized medicine approaches are essential for optimizing therapeutic outcomes in diverse patient populations.
Keywords:
HER2-positive breast cancerPI3K/AKT pathwaydrug resistancetargeted therapy

More Related Videos

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts10:27

Testing Targeted Therapies in Cancer using Structural DNA Alteration Analysis and Patient-Derived Xenografts

Published on: July 25, 2020

7.2K
Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma13:18

Network Pharmacology Prediction and Experimental Validation of Trichosanthes-Fritillaria thunbergii Action Mechanism Against Lung Adenocarcinoma

Published on: March 3, 2023

1.2K

Related Concept Videos

PI3K/mTOR/AKT Signaling Pathway01:22

PI3K/mTOR/AKT Signaling Pathway

The mammalian target of rapamycin  (mTOR) is a serine/threonine kinase that regulates growth, proliferation, and cell survival in response to hormones, growth factors, or nutrient availability. This kinase exists in two structurally and functionally distinct forms: mTOR complex 1  (mTORC1) and mTOR complex 2  (mTORC2). The first form (mTORC1) is composed of a rapamycin-sensitive Raptor and proline-rich Akt substrate, PRAS40. In contrast,  mTORC2 consists of a...
3.4K
mTOR Signaling and Cancer Progression03:03

mTOR Signaling and Cancer Progression

The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
3.7K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.4K
Mitogens and the Cell Cycle02:38

Mitogens and the Cell Cycle

Mitogens and their receptors play a crucial role in controlling the progression of the cell cycle. However, the loss of mitogenic control over cell division leads to tumor formation. Therefore, mitogens and mitogen receptors play an important role in cancer research. For instance, the epidermal growth factor (EGF) - a type of mitogen and its transmembrane receptor (EGFR), decides the fate of the cell's proliferation. When EGF binds to EGFR, a member of the ErbB family of tyrosine kinase...
6.4K
Interactions Between Signaling Pathways01:19

Interactions Between Signaling Pathways

Signaling cascades usually lack linearity. Multiple pathways interact and regulate one another, allowing cells to integrate and respond to diverse environmental stimuli.
Convergence and divergence, and cross-talk between signaling pathways
Two distinct signaling pathways can converge on a single functional unit, which may either be a single protein or a complex of proteins. The response is either functionally distinct or synergistic between the two pathways but different from the response...
6.2K
The JAK-STAT Signaling Pathway01:20

The JAK-STAT Signaling Pathway

Several cytokine receptors have tightly bound Janus kinase or JAK proteins attached at their cytosolic tail. Small signaling molecules such as cytokines, growth hormones, or prolactins bind to the cytokine receptors and initiate their dimerization. The dimerization brings the cytosolic JAKs together that trans-phosphorylate and activates each other. The activated JAKs now phosphorylate cytosolic tails of the cytokine receptors, which serve as binding sites for adaptor proteins such as  SH2...
8.7K